By David Stephen
Sedona, AZ — There is a new [April 18, 2026] report on NPR, Trump signs order fast tracking review of psychedelics for mental health disorders, stating that, “President Trump has signed an executive order to make certain psychedelic drugs more available to treat mental health conditions, such as depression and anxiety. He directed $50 million in federal funds to make them more accessible, and ordered the Food and Drug Administration to fast track a review of such drugs as psilocybin and ibogaine.”
“Next week, the FDA will issue national priority vouchers to three psychedelics, which the agency’s commissioner, Mary Makary, said will allow the review of those drugs to be approved quickly – perhaps in just weeks. This is the first time the FDA has offered to fast-track any psychedelics.”
“A 2025 study published in the Journal of the American Medical Association showed that a single dose of the psychedelic LSD could ease anxiety and depression for months.”
“Psilocybin and ibogaine are currently listed as Schedule I drugs, meaning they have “no currently accepted medical use and a high potential for abuse,” according to the U.S. Drug Enforcement Administration.”
There is a recent [April 6, 2026] paper in Nature, An international mega-analysis of psychedelic drug effects on brain circuit function, stating that, “We conducted a ‘mega-analysis’ integrating 11 independent resting-state functional magnetic resonance imaging datasets across five psychedelic drugs (psilocybin, lysergic acid diethylamide, mescaline, N,N-dimethyltryptamine and ayahuasca) from research groups spanning three continents and five countries. Most prominently, we identified a core signature of increased functional connectivity between transmodal (default, frontoparietal and limbic) and unimodal networks (visual and somatomotor), with subnetwork specificity. Furthermore, key subcortical regions (thalamus, caudate and putamen) and the cerebellum exhibited altered coupling with sensorimotor networks.”
There is another recent [February 6, 2026] paper in Nature, The science of psychedelic medicine, stating that, “Classic psychedelics typically act at the serotonin 5-HT2A receptor to profoundly alter brain function and consciousness.”
“We show that preclinical and human research findings converge on two complementary processes: acute neural desynchronization, which destabilizes entrenched network patterns, and subacute neuroplasticity, which opens a window for psychological and behavioral change.”
The Psychedelic Answer?
The problem of mental illness, including PTSD, is simply not the answer of psychedelics. It is the problem of even knowing what mental illness is.
Psychedelics would join existing classes of psychoactive substances [some of which are positive and some negative]. The quest — as some are beneficial, albeit with side-effects and some are harmful and addictive — is to really explore what happens in the mind, in direct mechanistic and components ways.
It should no longer just be about how psychedelics help or their general potential but really about what happens in the mind, with or without them.
It is already established that psychedelics “act at the serotonin 5-HT2A receptor”. Now, how does this tell the story of how they influence experiences, including making changes against mental states, including those of disorders?
This must be the conceptual adventure, such that exploring to answer, even as studies proceed, is to know what, how and why psychedelics act decisively on the brain.
Conceptual Neuroimaging
What must be defined are the chorus of electrical and chemical signals, under the action of psychedelics. Simply, psychedelics must be understood from the context of their influence across the efforts of electrical and chemical signals in different clusters of neurons.
The necessity for this is to make it better to prospect how it can be more broadly beneficial including limiting risks, as well as using psychedelics as a tangent to understand psychoactive substances, more broadly.
This is the possibility expressed in the postulation in Conceptual Biomarkers and Theoretical Biological Factors for Psychiatric and Intelligence Nosology.
Regulation
The Food and Drug Administration [FDA] and The National Institutes of Health [NIH], should not just assume that psychedelics should become a solely clinical leap, when it is possible that they can become the opportunity to get into defining the mind, mental and what it means to have order or disorder. This will be helpful to veterans mental health, across situations, avoiding some debilitating effects, sometimes.
There are several mental states that are simply a result of not knowing, such that knowing alone, even if approximately, would solve aspects of the problem.
This makes it vital to explore conceptual neuroimaging, for relays and destinations in the brain, across set of electrical and chemical signals, so that it is possible to know where the problem might be and what to do to solve them.
In psychiatry, it is often a new neurotechnology, a new substance, a new therapy and so forth. But what is the mind, what happens within, what are the extents of risks and what can be done, in the absence of a chemical or electrode intervention?
This is what the NIH and the FDA must ask, towards making progress. Even the NIH Brain Initiative, can explore to focus on this as well.
